Pharmaceuticals, Biotechnology and Life Sciences
Nordic Nanovector ASA (OSE: NANOV) has announced that its Nomination Committee has nominated Dr Thomas Ramdahl for election as a Non-executive Director at the Company’s Annual General Meeting (AGM) on 28 April 2022.
Nordic Nanovector has appointed Vivet Therapeutic’s chairman and former TiGenix’s CEO, Eduardo Bravo as its new Chief Executive Officer, the…
The US Food & Drug Administration (FDA) has granted Fast Track designation to Nordic Nanovector’s Betalutin (177Lu-lilotomab satetraxetan) for the treatment of…
Nordic Nanovector’s Chief Executive Officer Luigi Costa will step down, and the company will search for a new CEO immediately,…
Nordic Nanovector ASA has appointed Malene Brondberg as Vice President, Investor Relations and Corporate Communications. Malene will lead the engagement and…
Nordic Nanovector has appointed Dr. Reza Safaei, MD as Head of Medical Affairs to lead the development and execution of Nordic Nanovector’s medical affairs strategy for Betalutin.
Nordic Nanovector ASA has begin dosing patients in its Phase 1 Betalutin study, testing a CD37 targeting antibody-radionuclide conjugate, in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are ineligible for stem cell transplantation.